OKYO PharmaSTU:OK10 23 Current Ratio is 0.58 as of Sep. 2025, which is 82% below its 10-year median of 3.17. GuruFocus rates STU:OK10 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, OKYO Pharma ranks worse than 89.86% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. OKYO Pharma's current ratio for the quarter that ended in Sep. 2025 was 0.58.
OKYO Pharma has a current ratio of 0.58. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If OKYO Pharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for OKYO Pharma's Current Ratio or its related term are showing as below:
STU:OK10'
s Current Ratio Range Over the Past 10 Years
Min: 0.21 Med: 3.17 Max: 316.59
Current: 0.58
During the past 13 years, OKYO Pharma's highest Current Ratio was 316.59. The lowest was 0.21. And the median was 3.17.
STU:OK10's Current Ratio is ranked worse than 89.86% of 1410
companies
in the Biotechnology industry
Industry Median: 3.9
vs STU:OK10: 0.58
OKYO Pharma (STU:OK10) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
OKYO Pharma Current Ratio Related Terms
OKYO Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for OKYO Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OK10 vs ENTX, HRTX, RANI: Current Ratio Comparison
For the Biotechnology subindustry, OKYO Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OKYO Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OKYO Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where OKYO Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OKYO Pharma (STU:OK10) has a Current Ratio of 0.58 as of Sep. 2025. This is 82% below median its historical median of 3.17. Over the past decade, OKYO Pharma's Current Ratio has ranged from 0.21 to 316.59. According to the industry distribution chart, OKYO Pharma ranks #1267 out of 1410 companies in the Biotechnology industry, placing it in the top 89.9%.
Is OKYO Pharma's Current Ratio too high?
OKYO Pharma's current Current Ratio of 0.58 is 82% below median its 10-year median of 3.17. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 316.59. The Biotechnology industry median Current Ratio is 3.90. OKYO Pharma's value of 0.58 is 85.1% below this industry median. Based on the distribution chart, OKYO Pharma ranks #1267 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Current Ratio compare to ENTX and HRTX?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #1267 out of 1410 companies for Current Ratio. This places OKYO Pharma in the lower half of its industry. The industry median Current Ratio is 3.90. OKYO Pharma's value of 0.58 is 85.1% below this benchmark. Historically, OKYO Pharma's own Current Ratio has ranged from 0.21 to 316.59 over the past decade. While the company's 10-year median is 3.17 vs. the industry median of 3.90, OKYO Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OKYO Pharma's current Current Ratio of 0.58 is 85.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OKYO Pharma's current Current Ratio is 0.58, which is 82% below median its own 10-year median of 3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (STU:OK10) has a current Current Ratio of 0.58. The current Current Ratio is 0.58, which is 82% below median its 10-year median of 3.17 and 85.1% below the Biotechnology industry median of 3.90. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For OKYO Pharma (STU:OK10), the current Current Ratio is 0.58 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score
Get the complete analysis for STU:OK10
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OK10 has been successfully added to your 
